Transdermal Clonidine in Chronic Hemodialysis Patients

Inclusion Criteria: 1. signed informed consent; 2. age: 18years to 80 years old； 3. on hemodialysis for more than or equal to 3 months, not less than 3 times and 12 hours hemodialysis per week； 4. cardiac function grade I or grade II(NYHA)； 5. Using 1 or more than 1 oral antihypertensive drugs, pre-dialysis systolic blood pressure over 140mmHg or dialysis blood pressure over 90mmHg, post-dialysis systolic blood pressure over 130mmHg or diastolic blood pressure over 80mmHg Exclusion Criteria: 1. acute infection within 1 month； 2. acute myocardial infarction/cardiac function grade IV/stroke within 3months； 3. LVEF lower than 50% by echocardiography； 4. Dry weight is not suitable by BCM evaluation, more than plus or minus 1kg； 5. Inter-dialysis weight gain exceeds 5% of dry weight； 6. Post-dialysis systolic blood pressure lower than 120mmHg and diastolic blood pressure lower than 70mmHg； 7. Begin or stop recombinant human erythropoietin treatment within 2 weeks before inclusion or 10 weeks after inclusion; 8. Adjust recombinant human erythropoietin dosage to more than 2times or less than half original dosage within 2 weeks before inclusion or 10 weeks after inclusion； 9. The treatment regimen will be amended within 10 weeks and it is expected that the treatment amendment may affect blood pressure； 10. Pregnancy or lactation or planning a pregnancy in 10 weeks； 11. Expected to withdraw hemodialysis treatment in 10 weeks； 12. Allergic to clonidine or its accessories； 13. Undergoing other clinical studies, and the research interventions have an impact on blood pressure； 14. Other clinical conditions that may affect the results